U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07196410) titled 'KAN-004 for Immune-Related Diarrhea or Colitis' on Sept. 15.
Brief Summary: The goal of this clinical trial is to evaluate the safety and tolerability of KAN-004 in patients with immune-related colitis.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Colitis
Diarrhea Caused by Antitumor Drugs
Intervention:
BIOLOGICAL: KAN-004
Each dose of KAN-004 contains a consortium of bacteria isolated from the stool of healthy donors formulated as a powder in a capsule intended for oral administration
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Centre hospitalier de l'Universite de Montreal (CHUM)
Published by HT D...